With the rapid development of biotechnology and the deepening of precision medicine, antibody conjugated drugs (ADCs) are leading a new era of anti-tumor therapy. ADC drugs, also known as Antibody Drug Conjugates, consist of three parts: antibodies, linkers, and cytotoxic payloads. They combine the high specificity of antibodies with the efficient killing power of cytotoxic drugs, and are known as "biological missiles".